ParadigMS Foundation

Join this webinar and familiarise yourself with the robust European regulatory processes and effective oversight for generic, biosimilar, and follow-on non-biologic complex drugs (NBCDs) of disease modifying therapies in #MultipleSclerosis. This webinar will allow you to have informed conversations with your patients about the potential use of these agents. Speakers: ▫︎ Celia Oreja-Guevara ▫︎ Thomas Berger 🇬🇧🇩🇪 The session will be held in English. We offer simultaneous translation into German. Find out more: https://lnkd.in/e97mARR8 #paradigmsfoundation #webinar #ms #MScare #neurology

Learn more about MS prognostic tools and Artificial intelligence by Professor Bart Van Wijmeersch, Associate Professor of Neurology at the UHasselt.   In this on-demand #webinar, Prof. Van Wijmeersch focused on the integration of multiple prognostic factors and AI to tailor MS treatment to individual patient needs, aiming to improve long-term outcomes through personalized medicine. He emphasized the importance of considering each patient's unique prognosis when initiating treatment. Van Wijmeersch also explored how machine learning and AI can enhance the prediction of disability progression by integrating various clinical, imaging, and electrophysiological data points.   Don't miss out on these insights! Watch the webinar here: https://lnkd.in/eAtUKYzK   #MultipleSclerosis #AI #personalizedmedicine #healthcareinnovation

On Saturday, 7th September, ParadigMS will convene an #ExpertMeeting in Budapest, assembling top specialists in multiple sclerosis to review and discuss educational materials on MS treatment and care. The agenda includes new topics like consensus quality indicators for monitoring MS and the diagnosis and treatment of NMO/MOGAD, alongside final presentations on monitoring disease progression beyond EDSS. There will be a key discussion on how to uncover subtle or silent progressions and also the talks on the updates on prognosis factors in MS and future topics are foreseen. A detailed agenda will be shared soon. Stay tuned to our website or LinkedIn for updates! 😉

Professor Celia Oreja-Guevara delivered a talk on how Smoldering disease in #MultipleSclerosis underscores the need to view the disease as a continuum involving chronic inflammation, slow progression, and relapses. Understanding these interconnected manifestations can lead to more effective treatment strategies, aiming to minimize long-term disability and improve the quality of life for individuals with MS. This #webinar was presented at the first International Neuroimmunology Conference INIC in Saudi Arabia. Learn more and watch this insightful webinar by Prof. Oreja-Guevara on our website: https://lnkd.in/eXBeF6QN #eLearning #patientcare #ms

Our goal is to improve patient care for MS, NMOSD, and MOGAD by providing expertly curated learning materials and advanced, clinically relevant CME. By participating in our #survey, you help us create high-quality CME content tailored for neurologists and residents!

After years of work, our consensus paper on smouldering multiple sclerosis has been published. Let's hope the wider MS community adopt our terminology and recommendations. => https://buff.ly/3WJuhqB

Learn more about 𝗔𝘂𝘁𝗼𝗹𝗼𝗴𝗼𝘂𝘀 𝗛𝗲𝗺𝗮𝘁𝗼𝗽𝗼𝗶𝗲𝘁𝗶𝗰 𝗦𝘁𝗲𝗺 𝗖𝗲𝗹𝗹 𝗧𝗿𝗮𝗻𝘀𝗽𝗹𝗮𝗻𝘁𝗮𝘁𝗶𝗼𝗻 (AHSCT) in #MultipleSclerosis from Professor magd zakaria. Prof. Zakaria, the head of the Multiple Sclerosis Unit at the Ain Shams Specialized University Hospital, recently shared the latest advancements in AHSCT for MS at the first International Neuroimmunology Conference. The lecture detailed the types of stem cells, particularly hematopoietic stem cells, and their role in treating MS. Efficacy data from multiple studies and registries were reviewed, demonstrating the benefits of AHSCT in terms of event-free, progression-free, and relapse-free survival rates. The presentation emphasized the improved outcomes in early and aggressive MS cases, the significant reduction in treatment-related mortality, and the comparative efficacy of AHSCT over disease-modifying therapies (DMTs). #paradigmsfoundation #webinar #eLearning #patientcare #MScare

Our members are to core of our foundation, and today we're highlighting Dr. Mona Alkhawajah ⤵︎   Dr. Alkhawajah is a consultant neurologist specializing in Clinical Neuroimmunology and Multiple Sclerosis.   Did you know that Dr. Alkhawajah established the first Multiple Sclerosis support group in the Kingdom? The first meeting took place in June 2014. She is the organizer of the first (2015), second (2017), third (2019), and fourth (2023) “Walk for MS” in Saudi Arabia and is actively involved in educating the public about MS. She has made several public appearances on national and international TV, talking about MS and advocating for patients who have the disease. #paradigmsfoundation #neurology #multiplesclerosis #patientcare #healthcare #MScare  

ℹ️ Takeaways from the webinar on the use of generics, biosimilars, and non-biologic complex drugs for #MultipleSclerosis: • 𝗜𝗻 𝗘𝘂𝗿𝗼𝗽𝗲, 𝘁𝗵𝗲𝗿𝗲 𝗮𝗿𝗲 𝗿𝗼𝗯𝘂𝘀𝘁 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗽𝗿𝗼𝗰𝗲𝘀𝘀𝗲𝘀 specific for generics, biosimilars and follow-on NBCDs to ensure that in Europe these agents can be considered equally effective and safe as the originator Disease-Modifying Therapies (DMT). • 𝗖𝗼𝗻𝗰𝗲𝗿𝗻𝘀 𝗲𝘅𝗶𝘀𝘁 𝗮𝗯𝗼𝘂𝘁 𝘁𝗵𝗲 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 of such products in resource-limited settings where regulatory processes and post-marketing pharmacovigilance practices are less robust than in Europe. As these agents become more widely available, it is the responsibility of physicians caring for PwMS to familiarise themselves with the regulatory environment. • 𝗚𝗲𝗻𝗲𝗿𝗶𝗰𝘀, 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀 𝗮𝗻𝗱 𝗡𝗕𝗖𝗗𝘀, are pharmaceutical products designed to be similar to reference medicines but may have molecular differences due to their complex nature • 𝗕𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀 𝘂𝗻𝗱𝗲𝗿𝗴𝗼 𝗿𝗶𝗴𝗼𝗿𝗼𝘂𝘀 𝗰𝗼𝗺𝗽𝗮𝗿𝗮𝗯𝗶𝗹𝗶𝘁𝘆 assessments to demonstrate similarity in quality, safety, efficacy, and immunogenicity to the reference product, aiming to show no clinically meaningful differences. • 𝗚𝗲𝗻𝗲𝗿𝗶𝗰𝘀 𝗽𝗹𝗮𝘆 𝗮 𝗰𝗿𝘂𝗰𝗶𝗮𝗹 𝗿𝗼𝗹𝗲 in providing cost-effective alternatives while ensuring comparable therapeutic outcomes to their reference products. This webinar was led by two outstanding experts, Prof. Celia Oreja-Guevara (ESP) and Thomas Berger (AUT). A second session will be organised after summer! ☀️ #paradigmsfoundation #elearning #newsletter #patientcare

Learn more about 𝗠𝗦 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀: what is in the Pipeline - from Prof. Nicolaos Grigoriadis.   Nicolaos Grigoriadis is a Professor of Neurology at Aristotle University of Thessaloniki and Head of the B' Department of Neurology. During the first International Neuroimmunology Conference, he talked about advancements in treating multiple sclerosis (MS) - from general treatments like Copaxone and interferons to more targeted therapies, such as monoclonal antibodies, which focus on controlling T and B cell activity. Current research indicates that microglial cells play a crucial role in ongoing neurodegeneration and disability progression, suggesting the need for treatments targeting these cells. New therapies in the pipeline, such as anti-CD20 monoclonal antibodies and BTK inhibitors, show promise in addressing both B cells in the brain and microglial activity to better manage MS progression. You can watch this webinar for free on our website and read more about the impressive biography of Prof. Nicolaos Grigoriadis. #paradigmsfoundation #webinar